查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1866947

非那雄胺市場依給藥途徑、產品類型、規格、適應症、通路和最終用戶分類－2025-2032年全球預測

Finasteride Market by Route Of Administration, Product Type, Strength, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非那雄胺市場規模將成長至 1.5472 億美元，複合年成長率為 2.92%。

主要市場統計數據
基準年 2024 1.2288億美元
預計年份：2025年 1.2655億美元
預測年份：2032年 1.5472億美元
複合年成長率 (%) 2.92%

引言部分清楚地概述了非那雄胺在泌尿系統和皮膚科的臨床應用、製劑選擇和市場趨勢。

非那雄胺仍是泌尿系統和皮膚科領域重要的小分子治療藥物，對良性前列腺增生和男性型脫髮症有持續的臨床效用。該分子的安全性和有效性已透過數十年的臨床應用得到充分證實，而近期的臨床討論已轉向差異化製劑、患者依從性和風險溝通。隨著市場參與企業重新審視其產品組合和分銷策略，清晰了解製劑選擇、監管預期和終端用戶趨勢對於持續的商業性成功至關重要。

監管變革、製劑創新、遠距遠端醫療應用和供應鏈韌性如何重塑非那雄胺市場的競爭格局

非那雄胺市場正經歷著一場變革性的轉變，其驅動力包括監管政策的調整、製劑的創新以及臨床實踐模式的改變。品牌藥專利到期加劇了學名藥的激烈競爭，導致商業性重心轉向差異化製劑，例如外用溶液和泡沫劑，以及旨在提高耐受性和依從性的新型給藥系統。同時，臨床醫師和病患對個人化給藥策略（包括低劑量方案）的興趣日益濃厚，這推動了以1毫克和5毫克製劑為重點的產品研發。

評估2025年美國累積關稅對原料藥採購及成品藥製劑經濟效益的商業性影響

2025年美國累積關稅的實施，對依賴跨境供應鏈的非那雄胺生產商、經銷商和原料供應商而言，已成為關鍵的營運轉捩點。這些關稅針對活性藥物成分（API）進口和成品製劑，提高了到岸成本，迫使相關人員重新評估籌資策略。為此，許多企業正在加快與契約製造和API生產商的對話，尋求地理多元化，並尋找能夠降低關稅風險、同時又能保證產品品質和合規性的替代供應商。

詳細的細分分析揭示了給藥途徑、產品分類、劑量、臨床適應症、分銷管道和最終用戶環境如何驅動策略選擇。

了解按給藥途徑、產品類型、規格、適應症、分銷管道和最終用戶分類的市場細分，對於識別商業性機會和臨床價值的交匯點至關重要。給藥途徑分為口服和外用製劑，口服製劑再細分為膠囊和錠劑，外用製劑又細分為泡沫劑和溶液劑。這些差異對依從性、耐受性和市場定位具有實際意義。口服片劑和膠囊劑更受習慣於全身治療的配藥醫生的青睞，而外用泡沫劑和溶液劑則通常用於解決全身暴露問題和局部耐受性方面的考慮。

美洲、歐洲、中東和非洲以及亞太地區的區域特徵將決定監管方式、製造地和商業策略。

區域趨勢影響需求促進因素、法規結構與供應鏈考量。深入了解美洲、歐洲、中東和非洲以及亞太地區對於戰略規劃至關重要。在美洲，成熟的監管管道、完善的配製流程和廣泛的保險覆蓋範圍，使得口服和外用製劑的市場接受度都較為穩定。然而，支付方的嚴格審查和以價值為導向的合約條款正日益影響產品定位和報銷談判。此外，美洲擁有完善的臨床研究網路，有利於核准後監測和真實世界數據的產生。

競爭情報和商業情報揭示了創新者、非專利生產商和戰略聯盟如何推動差異化和商業化運作。

主要企業之間的競爭行為反映了在保護現有業務價值和透過製劑研發、生命週期管理和分銷管道創新實現差異化之間的平衡。品牌公司專注於透過製劑授權和針對特定適應症的宣傳來維護品牌價值，而非專利生產商則利用其規模、成本效益和分銷網路來擴大市場涵蓋範圍。跨國公司往往強調監管一致性和跨境供應的可靠性，而本土公司則通常在靈活性、本地市場知識和定價應對力方面競爭。

為製造商和相關人員提供切實可行的、優先排序的建議，以增強產品差異化、供應多元化、通路策略以及與支付方的合作。

為了獲得永續的競爭優勢，產業領導者應採取一系列協同措施，整合臨床差異化、供應鏈韌性和通路最佳化。首先，應投資於製劑多樣化，推廣局部用藥替代方案和便捷的給藥系統，以解決耐受性和依從性問題，同時以臨床證據支持局部暴露和安全性聲明。其次，應優先考慮原料藥(API) 和成品製劑的供應鏈多樣化，透過對多家地理位置分散的供應商進行資格認證，並考慮近岸生產方案，以降低關稅風險和物流中斷的影響。

我們採用透明、嚴謹的混合方法研究方法，將第二手資料綜合和對關鍵相關利益者的訪談與穩健的檢驗和品管相結合。

本分析的調查方法整合了多方面的證據，以確保研究結果的穩健性和可重複性，同時最大限度地減少偏差。全面的二級研究階段整合了同行評審文獻、監管指導文件、臨床試驗註冊資訊以及公開的行業和政策出版物，為臨床適應症、製劑科學和行業趨勢建立背景。一級研究則透過對臨床醫生、醫院藥劑師、採購專家、供應鏈專業人員和商業領袖進行結構化訪談，補充了上述資訊來源，以收集一線觀點並檢驗戰略意義。

權威的綜合分析強調，製劑設計、供應鏈韌性和跨職能執行是支撐非那雄胺策略成功的三大支柱。

總之，要駕馭非那雄胺市場，需要對製劑選擇、市場細分動態、區域差異以及新興政策阻力有深入的了解。專利產品的歷史地位與學名藥競爭之間的相互作用，促使商業性重心轉向透過外用製劑、低劑量策略和更強力的患者支持來實現差異化。同時，貿易政策的發展和關稅措施凸顯了供應鏈多元化以及與海關和貿易相關人員積極互動的重要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 推出新型外用非那雄胺製劑，可最大限度減少全身暴露和副作用。
  • 拓展遠端醫療平台：提供線上非那雄胺諮詢和配藥服務
  • 新興市場契約製造對非專利學名藥生產的投資激增
  • 越來越多的臨床試驗正在評估低劑量非那雄胺治療女性型脫髮症的治療方法
  • 數位化依從性監測解決方案的興起，用於追蹤患者對非那雄胺治療方案的依從性
  • 非那雄胺與局部生長因子合併使用以促進頭髮生長的聯合治療的出現
  • 品牌非那雄胺專利到期對定價策略和成本績效的學名藥上市的影響
  • 消費者對替代雄性激素抑制劑和天然來源的非那雄胺類似物在預防脫髮方面的興趣日益濃厚。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 非那雄胺市場依給藥途徑分類

  • 口服
    • 膠囊
    • 藥片
  • 外用藥物
    • 形式
    • 解決方案

9. 非那雄胺市場依產品類型分類

  • 品牌產品
    • 領先品牌
    • 授權品牌
  • 學名藥
    • 國內製造商
    • 跨國製造商

第10章 非那雄胺市場（依強度分類）

  • 1mg
  • 5mg

第11章 非那雄胺市場依適應症分類

  • 脫髮症
    • 女性型脫髮症
    • 雄性脫髮症
  • 良性攝護腺增生
    • 輕度良性前列腺增生
    • 中度至重度良性攝護腺增生

第12章 非那雄胺市場依通路分類

  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 製造商官方網站
    • 第三方電子零售商
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第13章 非那雄胺市場（以最終用戶分類）

  • 診所
    • 皮膚科診所
    • 泌尿系統診所
  • 居家醫療
    • 自我治療
  • 醫院
    • 私立醫院
    • 公立醫院

第14章 非那雄胺市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 非那雄胺市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國非那雄胺市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Limited
    • Lupin Limited
    • Sun Pharmaceutical Industries Limited
    • Cipla Limited
    • Aurobindo Pharma Limited
    • Alembic Pharmaceuticals Limited
Product Code: MRR-CD5A9334D4CB

The Finasteride Market is projected to grow by USD 154.72 million at a CAGR of 2.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 122.88 million
Estimated Year [2025] USD 126.55 million
Forecast Year [2032] USD 154.72 million
CAGR (%) 2.92%

An incisive introduction that frames clinical relevance, formulation choices, and market forces shaping finasteride strategy across urology and dermatology

Finasteride remains a pivotal small-molecule therapeutic across urology and dermatology, with enduring clinical utility for benign prostatic hyperplasia and androgenic alopecia. The molecule's safety and efficacy profile has been well-characterized through decades of clinical use, and recent clinical conversations have shifted toward differentiated formulations, patient adherence, and risk communication. As market participants recalibrate portfolios and distribution strategies, a clear understanding of formulation choices, regulatory expectations, and end-user dynamics is essential for sustained commercial success.

In parallel, healthcare systems are adapting to changing patterns of outpatient care, telemedicine-driven prescribing, and a more informed patient base seeking topical alternatives and lower-dose regimens. These trends are altering prescribing behavior and creating new opportunities for manufacturers able to demonstrate superior tolerability, convenience, or cost-effectiveness. Moreover, the interplay between branded innovators and generic manufacturers continues to shape clinical access and pricing dynamics, urging strategic clarity on product differentiation and lifecycle management.

This introduction frames the subsequent analysis by highlighting why formulation strategy, distribution channel optimization, and responsive regulatory engagement are core to navigating a market environment characterized by heightened competition and evolving patient expectations. The following sections unpack transformative forces, tariff impacts, segmentation nuances, regional variances, competitive behavior, tactical recommendations, methodological rigor, and concluding implications for leaders evaluating finasteride-related opportunities.

How regulatory evolution, formulation innovation, telemedicine adoption, and supply chain resilience are reshaping competitive positioning within the finasteride landscape

The finasteride landscape is undergoing transformative shifts driven by regulatory adaptation, formulation innovation, and changing clinical practice patterns. Patent expirations for originator products have facilitated robust generics competition, which in turn has shifted commercial emphasis toward formulation differentiation such as topical solutions and foams and novel delivery systems that address tolerability and adherence. Concurrently, clinicians and patients are increasingly attentive to individualized dosing strategies, including lower-strength regimens, which have catalyzed product development efforts focused on 1 mg and 5 mg presentations.

Meanwhile, digital health and telemedicine platforms are reshaping prescribing workflows, enabling remote consultations and direct-to-patient distribution that accelerate treatment initiation and follow-up. This evolution is complemented by more sophisticated pharmacovigilance and risk communication practices, prompting manufacturers to invest in patient education and post-marketing evidence generation. Additionally, supply chain resilience has become a strategic imperative after recent global disruptions, prompting companies to evaluate near-shore manufacturing, API sourcing diversification, and inventory management strategies.

Together, these shifts are rebalancing competitive dynamics: manufacturers that align clinical differentiation with channel strategies, regulatory foresight, and supply chain robustness stand to secure durable positioning. Conversely, firms that rely solely on price competition may face margin pressure and constrained growth opportunities as stakeholders prioritize value demonstrated through tolerability, convenience, and evidence of long-term outcomes.

Assessing the operational and commercial consequences of cumulative United States tariff measures introduced in 2025 that affect API sourcing and finished-dosage economics

The introduction of cumulative United States tariffs in 2025 has introduced a material operational inflection point for finasteride manufacturers, distributors, and ingredient suppliers that rely on cross-border supply chains. Tariff measures targeting active pharmaceutical ingredient imports and finished-dose products have raised landed costs and compelled stakeholders to reassess sourcing strategies. In response, many organizations are accelerating dialogues with contract manufacturers and API producers to explore geographic diversification and secure alternative suppliers that mitigate tariff exposure while maintaining quality and regulatory compliance.

In addition, the tariff environment has prompted a renewed emphasis on cost-to-serve analysis across distribution channels. Channel economics for hospital pharmacies, retail outlets, and online pharmacies are being re-evaluated to understand how added import duties affect pricing, reimbursement negotiations, and patient affordability. Manufacturers are increasingly modeling the downstream effects of tariffs on formulary positioning and payer conversations, and some are pursuing supply chain reconfiguration to minimize tariff incidence on finished products.

Finally, the tariffs have highlighted the importance of proactive regulatory and trade engagement. Firms that collaborate with trade advisors, customs authorities, and industry consortia are better positioned to identify exemptions, preferential trade pathways, and tariff mitigation approaches. As a result, strategic planning now increasingly integrates trade policy considerations, ensuring that product launches, inventory allocation, and contract negotiations account for tariff-driven cost volatility and the need for operational flexibility.

In-depth segmentation analysis revealing how formulation, product class, dosing, clinical indication, distribution pathways, and end-user settings drive strategic choices

Understanding how the market is segmented across route of administration, product type, strength, indication, distribution channel, and end user is central to identifying where commercial opportunity and clinical value intersect. The route of administration divides into oral and topical formulations, with oral presentations further categorized into capsule and tablet, and topical options further described as foam and solution. These distinctions have practical implications for adherence, tolerability, and positioning: oral tablets and capsules appeal to prescribers familiar with systemic therapy, while topical foams and solutions are often positioned to address concerns about systemic exposure and localized tolerability.

Product type segmentation differentiates branded from generic offerings, with branded products subdivided into innovator brands and licensed brands, and generic products distinguished between local manufacturers and multinational manufacturers. Each category carries implications for regulatory engagement, marketing spend, and payer negotiations. Strength segmentation centers on two clinically relevant doses, 1 mg and 5 mg, and these strengths inform therapeutic intent-lower-dose regimens often align with hair loss indications and higher strengths guide prostate-related therapy.

Indication segmentation separates androgenic alopecia from benign prostatic hyperplasia, with androgenic alopecia further delineated into female pattern hair loss and male pattern baldness, and benign prostatic hyperplasia split into mild BPH and moderate to severe BPH. Distribution channel analysis examines hospital pharmacy, online pharmacy, and retail pharmacy pathways; hospital pharmacies are segmented into private and public institutions, online pharmacies into manufacturer websites and third-party e-retailers, and retail pharmacies into chain and independent formats. End-user segmentation captures clinics, home care, and hospitals with clinics further distinguished between dermatology and urology clinics, home care emphasizing self-medication, and hospitals divided into private and public facilities. These layered segments guide product design, messaging strategy, pricing approach, and channel investments, thereby enabling precise targeting of clinician audiences, patient cohorts, and procurement stakeholders.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory approaches, manufacturing footprints, and commercial strategies

Regional dynamics shape demand drivers, regulatory frameworks, and supply chain considerations, and a granular understanding of the Americas, Europe Middle East & Africa, and Asia-Pacific regions is essential for strategic planning. In the Americas, mature regulatory pathways, established prescribing norms, and widespread insurance coverage create predictable adoption patterns for both oral and topical formulations; however, payer scrutiny and value-based contracting increasingly inform product positioning and reimbursement discussions. The Americas also feature advanced clinical research networks that facilitate post-authorization studies and real-world evidence generation.

In Europe Middle East & Africa, heterogeneity in regulatory requirements and healthcare financing creates a multifaceted landscape. European markets tend to have stringent pharmacovigilance expectations and centralized pricing negotiations, whereas Middle Eastern and African markets may prioritize access and cost-containment. Regional procurement mechanisms and variable patient awareness levels influence uptake of branded versus generic options, and manufacturers often adapt registration and commercial strategies to address local regulatory timelines and channel structures.

Asia-Pacific exhibits a dynamic mix of rapid manufacturing capacity expansion, active generic competition, and growing private-sector delivery. Several countries in the region are significant producers of active pharmaceutical ingredients and finished-dose medicines, which impacts global supply chains and the cost base. At the same time, rising patient awareness, expanding digital health adoption, and evolving regulatory harmonization efforts shape how products are launched and scaled. Together, these regional nuances govern go-to-market sequencing, partnership selection, and investment prioritization across product development, manufacturing footprint, and commercial operations.

Competitive and operational intelligence showing how innovators, generic manufacturers, and strategic partnerships drive differentiation and commercialization execution

Competitive behavior among key companies reflects a balance between protecting legacy franchise value and pursuing differentiation through formulation, lifecycle management, and channel innovation. Innovator companies have focused on maintaining brand relevance through licensed formulations and indication-specific communications, while generics manufacturers leverage scale, cost efficiencies, and distribution networks to capture broad access. Multinational manufacturers tend to emphasize regulatory consistency and cross-border supply reliability, whereas local manufacturers often compete on agility, local market knowledge, and price responsiveness.

Strategic initiatives commonly include licensing agreements, co-promotion partnerships, and selective acquisitions aimed at augmenting formulation portfolios or securing distribution reach in key regions. Clinical evidence generation and patient support programs are increasingly central to maintaining prescriber trust and facilitating long-term adherence, particularly where safety perceptions or tolerability concerns influence prescribing choices. Companies investing in topical platforms, lower-dose presentations, or combination approaches are positioning to address unmet tolerability or convenience gaps that can complement existing oral offerings.

Operationally, leaders are prioritizing supply chain security, regulatory agility, and digital engagement to support remote prescribing and direct-to-patient fulfillment. Those that integrate cross-functional capabilities-commercial, regulatory, medical, and manufacturing-are better equipped to execute rapid product modifications, respond to tariff-driven cost pressures, and negotiate effectively with payers and procurement entities. Overall, competitive dynamics reward companies that align scientific differentiation with pragmatic commercialization and operational resilience.

Practical and prioritized recommendations for manufacturers and stakeholders to strengthen formulation differentiation, supply diversity, channel strategy, and payer engagement

Industry leaders should pursue a coordinated set of actions that align clinical differentiation, supply chain resilience, and channel optimization to capture sustainable advantage. First, invest in formulation diversification by advancing topical alternatives and user-friendly delivery systems that address tolerability and adherence concerns, while ensuring clinical evidence supports claims of localized exposure and safety. Second, prioritize API and finished-dose supply chain diversification by qualifying multiple suppliers across geographies and considering near-shore manufacturing options to mitigate tariff exposure and logistical disruption.

Third, refine channel strategies to reflect evolving patient and prescriber behaviors; this includes strengthening direct-to-patient capabilities through manufacturer websites, partnering with reputable third-party e-retailers for broader reach, and supporting hospital and clinic procurement teams with targeted clinical and economic evidence. Fourth, enhance lifecycle management by strategically aligning branded and licensed offerings with generics strategies, using real-world evidence and post-marketing surveillance to sustain clinician confidence and payer negotiations. Fifth, engage early and constructively with payers, procurement bodies, and regulatory agencies to shape reimbursement pathways and to explore tariff mitigation measures or preferential trade arrangements.

Finally, invest in digital engagement and patient support programs that bolster adherence and long-term outcomes, while using data analytics to understand channel economics and to optimize inventory allocation. By implementing these coordinated steps, leaders can reduce risk, unlock differentiating value propositions, and position portfolios for resilient performance in an increasingly complex environment.

A transparent and rigorous mixed-methods research approach combining secondary synthesis and primary stakeholder interviews with robust triangulation and quality control

The research methodology underpinning this analysis integrates multiple evidence streams to ensure robust, reproducible insights and to minimize bias. A comprehensive secondary research phase synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and open-source trade and policy publications to establish context on clinical indications, formulation science, and trade dynamics. Primary research complemented these sources through structured interviews with clinicians, hospital pharmacists, procurement specialists, supply chain experts, and commercial leaders to capture on-the-ground perspectives and validate strategic implications.

Data triangulation was applied across qualitative inputs and documented sources to reconcile divergent viewpoints and to strengthen confidence in thematic findings. The segmentation framework was developed iteratively, mapping route of administration, product type, strength, indication, distribution channel, and end user to real-world prescribing and procurement behaviors. Quality control procedures included cross-validation of interview transcripts, source auditing, and peer review by subject matter experts to ensure factual accuracy and methodological transparency.

Ethical and compliance standards guided research conduct, protecting respondent confidentiality and ensuring that conclusions were evidence-based. The resulting methodological approach prioritizes replicability and traceability so that stakeholders can understand how insights were derived and apply them to strategic planning, commercialization roadmaps, and operational decision-making.

A conclusive synthesis emphasizing formulation, supply chain resilience, and cross-functional execution as the pillars of successful finasteride strategies

In conclusion, navigating the finasteride landscape requires a nuanced appreciation of formulation choices, segmentation dynamics, regional variations, and emerging policy headwinds. The interplay of patented product legacies and generics competition has shifted commercial emphasis toward differentiation through topical formulations, lower-dose strategies, and stronger patient support. Simultaneously, trade policy developments and tariff measures have underscored the strategic importance of supply chain diversification and proactive engagement with customs and trade stakeholders.

For decision-makers, the priority is to translate these insights into cohesive strategies that align clinical differentiation with channel tactics and operational resilience. This means investing in evidence generation to support new formulations, securing multi-source supply options to mitigate tariff and logistical risk, and adapting commercialization models to a landscape increasingly shaped by telemedicine and direct-to-patient channels. Continued collaboration across functions-medical affairs, regulatory, supply chain, and commercial-will be essential to execute these strategies effectively.

Ultimately, success in this environment will favor organizations that combine scientific rigor, regulatory foresight, and commercial agility to meet clinician expectations and patient needs while managing cost and access dynamics. The following call to action outlines how to obtain the detailed report and arrange a strategic briefing to operationalize these findings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of new topical finasteride formulations to minimize systemic exposure and side effects
  • 5.2. Expansion of telehealth platforms providing virtual finasteride consultations and prescription services
  • 5.3. Surge in investment in generic finasteride production by contract manufacturers in emerging markets
  • 5.4. Increasing clinical trials evaluating low-dose finasteride treatment regimens for female pattern hair loss
  • 5.5. Rise of digital adherence monitoring solutions to track patient compliance with finasteride therapy schedules
  • 5.6. Emergence of combination therapies pairing finasteride with topical growth factors for enhanced hair regrowth outcomes
  • 5.7. Impact of branded finasteride patent expirations on pricing strategies and entry of value oriented generics
  • 5.8. Growing consumer interest in alternative androgen inhibitors and natural finasteride analogs for hair loss prevention

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Finasteride Market, by Route Of Administration

  • 8.1. Oral
    • 8.1.1. Capsule
    • 8.1.2. Tablet
  • 8.2. Topical
    • 8.2.1. Foam
    • 8.2.2. Solution

9. Finasteride Market, by Product Type

  • 9.1. Branded
    • 9.1.1. Innovator Brands
    • 9.1.2. Licensed Brands
  • 9.2. Generic
    • 9.2.1. Local Manufacturer
    • 9.2.2. Multinational Manufacturer

10. Finasteride Market, by Strength

  • 10.1. 1 Mg
  • 10.2. 5 Mg

11. Finasteride Market, by Indication

  • 11.1. Androgenic Alopecia
    • 11.1.1. Female Pattern Hair Loss
    • 11.1.2. Male Pattern Baldness
  • 11.2. Benign Prostatic Hyperplasia
    • 11.2.1. Mild BPH
    • 11.2.2. Moderate To Severe BPH

12. Finasteride Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
    • 12.1.1. Private Hospital
    • 12.1.2. Public Hospital
  • 12.2. Online Pharmacy
    • 12.2.1. Manufacturer Website
    • 12.2.2. Third Party E-Retailer
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. Finasteride Market, by End User

  • 13.1. Clinics
    • 13.1.1. Dermatology Clinics
    • 13.1.2. Urology Clinics
  • 13.2. Home Care
    • 13.2.1. Self Medication
  • 13.3. Hospitals
    • 13.3.1. Private Hospitals
    • 13.3.2. Public Hospitals

14. Finasteride Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Finasteride Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Finasteride Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Merck & Co., Inc.
    • 17.3.2. Teva Pharmaceutical Industries Ltd.
    • 17.3.3. Viatris Inc.
    • 17.3.4. Sandoz International GmbH
    • 17.3.5. Dr. Reddy's Laboratories Limited
    • 17.3.6. Lupin Limited
    • 17.3.7. Sun Pharmaceutical Industries Limited
    • 17.3.8. Cipla Limited
    • 17.3.9. Aurobindo Pharma Limited
    • 17.3.10. Alembic Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL FINASTERIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS FINASTERIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL FINASTERIDE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. FINASTERIDE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. FINASTERIDE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FINASTERIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FINASTERIDE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FINASTERIDE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS FINASTERIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS FINASTERIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS FINASTERIDE MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS FINASTERIDE MARKET SIZE, BY STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS FINASTERIDE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS FINASTERIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS FINASTERIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS FINASTERIDE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS FINASTERIDE MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA FINASTERIDE MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA FINASTERIDE MARKET SIZE, BY STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA FINASTERIDE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA FINASTERIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. NORTH AMERICA FINASTERIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. NORTH AMERICA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. NORTH AMERICA FINASTERIDE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 337. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 338. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 339. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 340. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 342. LATIN AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 344. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 345. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 346. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 347. LATIN AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 348. LATIN AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 349. LATIN AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. LATIN AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 351. LATIN AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 352. LATIN AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 353. LATIN AMERICA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)

TABLE 35